We believe that genetic analyses and insight can cut the high costs of drug development by reducing attrition rates for drug candidates and identify subsets of patients who will benefit the most from such treatments. By developing better drugs more quickly, we can help patients whose current treatment options are inadequate. We have already built the largest and best curated data resource of its kind in the world (comprising more than 7,000 traits and diseases) and have developed breakthrough machine learning algorithms that use data at scale to learn directly about human biology. In August 2018, we closed an over-subscribed £25 million financing round (Series B) which was led by Vertex Pharmaceuticals, with a second close of Series B completing in December 2018 bringing the total raised in the round to £33 million. We also announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. Genomics plc has an expert cross-disciplinary team, primarily scientists and software engineers, with offices in Oxford and Cambridge.
